Compare Aigan Co., Ltd. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROE of 0.11%
- The company has been able to generate a Return on Equity (avg) of 0.11% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of 2.22% and Operating profit at 17.99% over the last 5 years
3
The company has declared negative results in Mar'2026 after 2 consecutive positive quarters
4
With ROE of 2.25%, it has a expensive valuation with a 0.46 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
JPY 4,700 Million (Micro Cap)
20.00
NA
0.45%
-0.34
2.25%
0.38
Revenue and Profits:
Net Sales:
3,635 Million
(Quarterly Results - Mar 2026)
Net Profit:
-11 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2.68%
0%
2.68%
6 Months
20.72%
0%
20.72%
1 Year
77.48%
0%
77.48%
2 Years
48.07%
0%
48.07%
3 Years
47.25%
0%
47.25%
4 Years
48.89%
0%
48.89%
5 Years
18.58%
0%
18.58%
Aigan Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.22%
EBIT Growth (5y)
17.99%
EBIT to Interest (avg)
-366.40
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.36
Sales to Capital Employed (avg)
1.23
Tax Ratio
96.91%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0.11%
Valuation key factors
Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
0.46
EV to EBIT
9.43
EV to EBITDA
4.27
EV to Capital Employed
0.17
EV to Sales
0.09
PEG Ratio
0.08
Dividend Yield
0.37%
ROCE (Latest)
1.79%
ROE (Latest)
2.25%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
3,635.00
3,649.00
-0.38%
Operating Profit (PBDIT) excl Other Income
88.00
25.00
252.00%
Interest
0.00
0.00
Exceptional Items
-36.00
0.00
Consolidate Net Profit
-11.00
6.00
-283.33%
Operating Profit Margin (Excl OI)
11.00%
-5.50%
1.65%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -0.38% vs -14.24% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -283.33% vs -97.70% in Dec 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
15,283.00
14,863.00
2.83%
Operating Profit (PBDIT) excl Other Income
399.00
51.00
682.35%
Interest
0.00
0.00
Exceptional Items
-50.00
-88.00
43.18%
Consolidate Net Profit
155.00
3.00
5,066.67%
Operating Profit Margin (Excl OI)
14.80%
-8.60%
2.34%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 2.83% vs 1.40% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 5,066.67% vs 101.66% in Mar 2025
About Aigan Co., Ltd. 
Aigan Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






